Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings.

ABSTRACT:

Background

Trastuzumab deruxtecan (T-DXd) has been approved for a third- or later-line treatment of HER2-positive advanced gastric cancer (AGC) in Japan. However, clinical data on the use of T-DXd in real-world practice remain insufficient. Although early tumor shrinkage (ETS) serves as an early on-treatment indicator of high treatment sensitivity, the use of ETS in predicting T-DXd efficacy remains unclear.

Objectives

This study aimed to evaluate the clinical efficacy and safety of T-DXd and investigate the clinical utility of ETS as a predictor of long-term efficacy and survival.

Design

Single-center retrospective cohort study.

Methods

This study consecutively enrolled patients with HER2-positive AGC who received T-DXd as a third- or later-line treatment betw

SUBMITTER: Fukuda K 

PROVIDER: S-EPMC12035244 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature